Bevacizumab with chemotherapy in patients with KRAS wild-type metastatic colorectal cancer: Czech registry data | Future Oncology
Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study - ScienceDirect
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial - The Lancet Oncology
Frontiers | FOLFOXIRI/Bevacizumab Plus Nivolumab as First-Line Treatment in Metastatic Colorectal Cancer RAS/BRAF Mutated: Safety Run-In of Phase II NIVACOR Trial
Benefits & Risks of Treatment | Metastatic Colorectal Cancer (mCRC)| Avastin® (bevacizumab)
Neoadjuvant therapy of bevacizumab in combination with oxaliplatin and capecitabine (XELOX) for patients with metastatic colorectal cancer with unresectable liver metastases: a phase II, open‐label, single‐arm, noncomparative trial - Chen - 2018 -
How we treat metastatic colorectal cancer - ESMO Open
Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model
Xeloda – Treatment for Metastatic Colorectal Cancer - Clinical Trials Arena
New Colon Chemotherapy
Effects of bevacizumab (Avastin ® ) and capecitabine (Xeloda ® ) on the... | Download Scientific Diagram
Trifluridine/Tipiracil Combination Misses Mark in Metastatic Colon Cancer | MedPage Today
Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer | British Journal of Cancer
Colorectal Cancer – Treatments | Gastrointestinal Cancer
Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer | BMC Cancer
Capecitabine (Xeloda) for Colon Cancer | ChemoExperts
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial - The Lancet Oncology
Effects of bevacizumab (Avastin ® ) and capecitabine (Xeloda ® ) on the... | Download Scientific Diagram
Bevacizumab (Avastin®) as maintenance therapy after first progression on bevacizumab for patients with advanced colorectal carcinoma | Semantic Scholar
Use of Bevacizumab in the Maintenance Setting for Patients with Metastatic Colorectal Cancer (mCRC) | Research To Practice
Xeloda – Treatment for Metastatic Colorectal Cancer - Clinical Trials Arena
Avastin with Xeloda as a first-line treatment for metastatic breast cancer bc_en | PDF
First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study | British Journal of Cancer
Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model
Colorectal Cancer – Treatments | Gastrointestinal Cancer
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook - Cancer Treatment Reviews
Effects of bevacizumab (Avastin ® ) and capecitabine (Xeloda ® ) on the... | Download Scientific Diagram
